Pembrolizumab - Biosimilar
Product Description
Blau Farmaceutical S.A
-
Country/Region:Brazil
-
On CPHI since:2015
-
Certificates:3
-
Employees:1000 - 4999
Company types
Primary activities
Categories
Blau Farmaceutical S.A
-
Country/Region:Brazil
-
On CPHI since:2015
-
Certificates:3
-
Employees:1000 - 4999
Company types
Primary activities
More Products from Blau Farmaceutical S.A (3)
-
Product Anti PD1 - Biosimilar
Our product is currently in the early stages of development, with preclinical studies planned to start in the coming months as part of a structured development program.
The program is being designed to meet all clinical, regulatory, documentation, and manufacturing requirements for the world's m... -
Product IL-23 - Biosimilar
Our product is currently in the early stages of development, with preclinical studies planned to start in the coming months as part of a structured development program.
The program is being designed to meet all clinical, regulatory, documentation, and manufacturing requirements for the world's m... -
Product IgG4 - Biosimilar
Our product is currently in the early stages of development, with preclinical studies planned to start in the coming months as part of a structured development program.
The program is being designed to meet all clinical, regulatory, documentation, and manufacturing requirements for the world's m...
Blau Farmaceutical S.A resources (3)
-
News Blau Farmacêutica Fully Develops One of the World's Most Advanced Biosimilars Immunotherapies
Com a certificação de Boas Práticas de Fabricação (BPF) concedida pela ANVISA e o avanço das regulamentações internacionais, o acesso à imunoterapia contra o câncer no Brasil poderá ser transformado.
-
Report Sustainability Report 2025
Check out our 2025 Sustainability Report. This document reflects our commitment to sustainable and responsible practices across all our operations, helping preserve the present while contributing to a more equitable and balanced future.
The report provides an overview of our key achievements over the past year:
Advances in Research, Development, and Innovation;Investments in Social Projects, reinforcing our commitment to the communities where we operate;Progress in implementing best practices across our industrial processes, contributing to waste reduction.Sustainability is an integral part of our business strategy and embedded in our culture. We believe that building a better future starts with responsible decisions made today, integrating social, environmental, and governance principles into everything we do.
-
Datasheet Blaū Pharmaceutical - Innovation in health for the World
Blaū Pharmaceutical is a regional company with a strong presence across Latin America, a leader in the hospital pharmaceutical segment* and a pioneer in biotechnology in Brazil.
We are a publicly traded company listed on the Brazilian Stock Exchange (B3) under the ticker “Blau3.” Our commitment is to deliver innovative specialty medicines that ensure efficacy, safety, and quality, providing patients with the best therapeutic options, as determined by their medical teams and/or healthcare professionals.
With a broad portfolio of proprietary specialty medicines, we operate in key therapeutic areas such as immunology, hematology, oncology, nephrology, infectious diseases, anesthesiology, and others.
We are structured into three business units: Onco-Hemato & Specialties, Pharma/Retail, and Aesthetics, each with its own commercial and marketing teams, as well as independent financial management.